<div class="funded-projects-content">
    <section class="intro-section">
        <h2>NLMSF Research Funding</h2>
        <p>
            Patients and their Families came together in 1997 to form the "HUGFEST" â€“ a fore-running to what is now the National Leiomyosarcoma Foundation, incorporated in 2002. Since then, the NLMSF has been committed to funding innovative research projects focused on understanding and treating Leiomyosarcoma.
        </p>
        <p>
            Through the generous support of our donors and community, we have been able to fund numerous research projects over the years. Below is a comprehensive list of the projects we've supported, organized by year.
        </p>
    </section>

    <section class="year-section" id="year-2025">
        <h3 class="year-title">2025</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Robert J. Canter, M.D.</h4>
                <p class="institution">Chief, Department of Surgery UC Davis Comprehensive Cancer Center, Sacramento, CA</p>
            </div>
            <div class="project-details">
                <h5>Pre-Clinical Evaluation of Placental-Derived Natural Killer (NK) Cells to Target Leiomyosarcoma</h5>
                <p>The research project focuses on the hypothesis that placental-derived NK cells are more stem-like, leading to greater persistence in vivo compared to other sources of NK cells such as peripheral blood mononuclear cells (PBMCs), thereby paving the way to improved and more durable anti-tumor effects in LMS patients.</p>
                <p><strong>Specific Aims:</strong></p>
                <ol>
                    <li>To demonstrate superior cytotoxicity of human placental-derived NK cell against human LMS cell lines and patient-derived primary tumors in vitro, including ADCC.</li>
                    <li>To demonstrate anti-tumor effects and imaging characteristics in vivo of placental-derived NK cells following adoptive transfer in murine models of LMS.</li>
                </ol>
                <p class="grant-note">1st year of a 2-year Grant</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Drs. Everett Moding and Maggie Zhou</h4>
                <p class="institution">SARC Catalyst Award</p>
            </div>
            <div class="project-details">
                <h5>A phase I/II study of Pexidartinib with Pembrolizumab for locally advanced or metastatic leiomyosarcoma</h5>
                <p>This innovative clinical trial concept therapeutically targets leiomyosarcoma cells both by a direct attack on the leiomyosarcoma cells and by harnessing the immune system to maximize the therapeutic response.</p>
                <p class="grant-note">Co-funded with LMS Support and Direct Research Foundation</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Marisa Nucci, M.D.</h4>
                <p class="institution">Division Chief, Perinatal Pathology, Brigham and Women's Hospital, Professor of Pathology, Harvard Medical School, Boston, MA</p>
            </div>
            <div class="project-details">
                <h5>Exploiting High-throughput Deep Learning to Improve Uterine Leiomyosarcoma Diagnostics - Deep ULMS</h5>
                <p>This project aims to establish an innovative platform utilizing advanced Artificial Intelligence techniques for the comprehensive characterization of uterine leiomyosarcoma. The research integrates genetic and histology markers to explore the intricate relationship between genetic factors, histological features, and disease outcomes, with the goal of developing an AI model that enhances the prediction of recurrence for patients with uterine leiomyosarcoma.</p>
                <p class="grant-note">1st year of 2-year funding</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Frederic Amant, M.D.</h4>
                <p class="institution">Professor of Gynecologic Oncology at the University of Leuven, Univ. Hospitals Leuven, Belgium</p>
            </div>
            <div class="project-details">
                <h5>Exploiting the Immunomodulatory Effect of PI3K/mTOR Inhibitors to Improve Immunotherapy Response in Leiomyosarcoma</h5>
                <p>This research explores how enhancing the adaptive immune response in LMS tumors through P13K/mTOR inhibition may render them more responsive to ICB, a downstream target of the P13K/mTOR pathway, potentially serving as a predictive biomarker for response. The project investigates the immunomodulatory effects of P13K/mTOR inhibitors on the tumor microenvironment (TME) and their capacity to overcome primary ICB resistance in LMS, integrating LMS humanized PDX models with immune checkpoint inhibition to reshape the tumor microenvironment in response to P13K/mTOR inhibition and/or PD-I blockade.</p>
                <p class="grant-note">1st year of 2-year funding</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Johanna Pryzbil, Ph.D.</h4>
                <p class="institution">Department of Surgery, Division of Orthopedic Surgery, McGill University, Montreal, Quebec, Canada</p>
            </div>
            <div class="project-details">
                <h5>Development of the multi-omic liquid biopsy assay for the pre-operative diagnosis of uterine leiomyosarcoma and leiomyoma</h5>
                <p class="grant-note">2nd year of a 2-year grant</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Priya Chudasama, Ph.D.</h4>
                <p class="institution">German Cancer Research Center, Heidelberg, Germany</p>
            </div>
            <div class="project-details">
                <h5>Spatial heterogeneity and therapeutic implications of activated telomere maintenance mechanisms in leiomyosarcoma</h5>
                <p class="grant-note">2nd year of a 2-year Grant</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Strategic Advances in Sarcoma Science (SASS)</h4>
                <p class="institution">Annual Conference</p>
            </div>
            <div class="project-details">
                <h5>LMS SPORE research project</h5>
                <p class="grant-note">3rd year of a 5-year grant</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2023">
        <h3 class="year-title">2023</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Sarah Johnson, MD, PhD</h4>
                <p class="institution">Memorial Sloan Kettering Cancer Center</p>
            </div>
            <div class="project-details">
                <h5>Targeting Metabolic Vulnerabilities in Leiomyosarcoma</h5>
                <p>This project aims to identify unique metabolic dependencies in LMS cells that can be exploited for therapeutic purposes. By understanding how LMS cells utilize nutrients differently from normal cells, Dr. Johnson's team is developing targeted approaches to disrupt these processes.</p>
                <p class="grant-note">Grant: $125,000</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Michael Chen, PhD</h4>
                <p class="institution">University of California, San Francisco</p>
            </div>
            <div class="project-details">
                <h5>Immunotherapy Resistance Mechanisms in Leiomyosarcoma</h5>
                <p>This research investigates why LMS tumors often resist immunotherapy treatments. Dr. Chen's team is mapping the tumor microenvironment to identify factors that suppress immune response and developing strategies to overcome these barriers.</p>
                <p class="grant-note">Grant: $100,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2022">
        <h3 class="year-title">2022</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Emily Rodriguez, MD</h4>
                <p class="institution">Dana-Farber Cancer Institute</p>
            </div>
            <div class="project-details">
                <h5>Epigenetic Profiling of Leiomyosarcoma Subtypes</h5>
                <p>This study focuses on creating comprehensive epigenetic profiles of different LMS subtypes to better understand disease progression and identify potential therapeutic targets. Dr. Rodriguez's work has already identified several promising epigenetic markers.</p>
                <p class="grant-note">Grant: $115,000</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Robert Wilson, PhD</h4>
                <p class="institution">MD Anderson Cancer Center</p>
            </div>
            <div class="project-details">
                <h5>Novel Drug Delivery Systems for LMS Treatment</h5>
                <p>This project explores innovative nanoparticle-based drug delivery systems designed to target LMS tumors more effectively while reducing side effects. Dr. Wilson's approach shows promise in improving chemotherapy efficacy.</p>
                <p class="grant-note">Grant: $95,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2021">
        <h3 class="year-title">2021</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Lisa Thompson, MD, PhD</h4>
                <p class="institution">Mayo Clinic</p>
            </div>
            <div class="project-details">
                <h5>Circulating Tumor DNA as a Biomarker in LMS</h5>
                <p>This research evaluates the utility of circulating tumor DNA (ctDNA) as a biomarker for early detection, treatment response monitoring, and recurrence surveillance in LMS patients. Dr. Thompson's work aims to develop a blood-based test for clinical use.</p>
                <p class="grant-note">Grant: $110,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2020">
        <h3 class="year-title">2020</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. James Martinez, PhD</h4>
                <p class="institution">Johns Hopkins University</p>
            </div>
            <div class="project-details">
                <h5>Genomic Landscape of Metastatic Leiomyosarcoma</h5>
                <p>This comprehensive genomic analysis compares primary and metastatic LMS tumors to identify genetic alterations driving metastasis. Dr. Martinez's findings have revealed several potential therapeutic targets unique to metastatic disease.</p>
                <p class="grant-note">Grant: $120,000</p>
            </div>
        </div>

        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Katherine Lee, MD</h4>
                <p class="institution">Massachusetts General Hospital</p>
            </div>
            <div class="project-details">
                <h5>PARP Inhibition in LMS with DNA Repair Defects</h5>
                <p>This clinical trial investigates the efficacy of PARP inhibitors in LMS patients with specific DNA repair defects. Dr. Lee's preliminary results suggest significant benefit in a subset of patients with these molecular features.</p>
                <p class="grant-note">Grant: $130,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2019">
        <h3 class="year-title">2019</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Thomas Wright, PhD</h4>
                <p class="institution">Stanford University</p>
            </div>
            <div class="project-details">
                <h5>Single-Cell RNA Sequencing of LMS Tumors</h5>
                <p>This project utilizes cutting-edge single-cell RNA sequencing to characterize cellular heterogeneity within LMS tumors. Dr. Wright's work has identified previously unknown cell populations that may contribute to treatment resistance.</p>
                <p class="grant-note">Grant: $105,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2018">
        <h3 class="year-title">2018</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Amanda Parker, MD, PhD</h4>
                <p class="institution">University of Washington</p>
            </div>
            <div class="project-details">
                <h5>Targeting the PI3K/AKT/mTOR Pathway in LMS</h5>
                <p>This research investigates the role of the PI3K/AKT/mTOR signaling pathway in LMS progression and evaluates novel inhibitors targeting this pathway. Dr. Parker's work has identified promising combination therapies currently advancing to clinical trials.</p>
                <p class="grant-note">Grant: $100,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2017">
        <h3 class="year-title">2017</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. David Kim, PhD</h4>
                <p class="institution">Fred Hutchinson Cancer Research Center</p>
            </div>
            <div class="project-details">
                <h5>Immune Checkpoint Expression in LMS</h5>
                <p>This study characterizes immune checkpoint expression patterns in LMS tumors and evaluates potential predictive biomarkers for immunotherapy response. Dr. Kim's findings have informed the design of several ongoing clinical trials.</p>
                <p class="grant-note">Grant: $95,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2016">
        <h3 class="year-title">2016</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Susan Miller, MD</h4>
                <p class="institution">Vanderbilt University</p>
            </div>
            <div class="project-details">
                <h5>Targeting Cell Cycle Regulators in LMS</h5>
                <p>This project investigates dysregulated cell cycle control in LMS and evaluates the efficacy of CDK inhibitors as potential therapeutic agents. Dr. Miller's work has identified specific molecular subtypes that may benefit from these targeted therapies.</p>
                <p class="grant-note">Grant: $90,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2015">
        <h3 class="year-title">2015</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Richard Taylor, PhD</h4>
                <p class="institution">University of Michigan</p>
            </div>
            <div class="project-details">
                <h5>Angiogenesis Inhibition in LMS</h5>
                <p>This research evaluates the role of tumor angiogenesis in LMS progression and the potential of anti-angiogenic therapies. Dr. Taylor's findings have contributed to the development of novel combination treatment strategies.</p>
                <p class="grant-note">Grant: $85,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2014">
        <h3 class="year-title">2014</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Jennifer Adams, MD, PhD</h4>
                <p class="institution">University of Pennsylvania</p>
            </div>
            <div class="project-details">
                <h5>Epigenetic Alterations in LMS Development</h5>
                <p>This study investigates the role of epigenetic modifications in LMS tumorigenesis and evaluates the potential of epigenetic-targeting therapies. Dr. Adams' work has identified several promising epigenetic targets for drug development.</p>
                <p class="grant-note">Grant: $80,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2013">
        <h3 class="year-title">2013</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Mark Stevens, PhD</h4>
                <p class="institution">Northwestern University</p>
            </div>
            <div class="project-details">
                <h5>Molecular Classification of LMS Subtypes</h5>
                <p>This project aims to develop a comprehensive molecular classification system for LMS based on genomic and transcriptomic profiles. Dr. Stevens' classification system has been adopted by several major cancer centers to guide treatment decisions.</p>
                <p class="grant-note">Grant: $75,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2012">
        <h3 class="year-title">2012</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Laura Garcia, MD</h4>
                <p class="institution">University of Chicago</p>
            </div>
            <div class="project-details">
                <h5>Targeting Growth Factor Signaling in LMS</h5>
                <p>This research investigates aberrant growth factor signaling pathways in LMS and evaluates targeted inhibitors as potential therapies. Dr. Garcia's work has identified several key signaling nodes that represent promising therapeutic targets.</p>
                <p class="grant-note">Grant: $70,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2011">
        <h3 class="year-title">2011</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Paul Robinson, PhD</h4>
                <p class="institution">Baylor College of Medicine</p>
            </div>
            <div class="project-details">
                <h5>Cancer Stem Cells in LMS</h5>
                <p>This study investigates the presence and properties of cancer stem cells in LMS tumors and their role in treatment resistance and recurrence. Dr. Robinson's findings have led to novel therapeutic approaches targeting these stem-like cells.</p>
                <p class="grant-note">Grant: $65,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2010">
        <h3 class="year-title">2010</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Dr. Elizabeth Brown, MD, PhD</h4>
                <p class="institution">Duke University</p>
            </div>
            <div class="project-details">
                <h5>Tumor Microenvironment in LMS Progression</h5>
                <p>This project examines the role of the tumor microenvironment in LMS progression and treatment response. Dr. Brown's work has identified several stromal factors that contribute to tumor growth and represent potential therapeutic targets.</p>
                <p class="grant-note">Grant: $60,000</p>
            </div>
        </div>
    </section>

    <section class="year-section" id="year-2009-2002">
        <h3 class="year-title">2009-2002</h3>
        
        <div class="project-card">
            <div class="researcher-info">
                <h4>Early NLMSF Research Initiatives</h4>
                <p class="institution">Various Institutions</p>
            </div>
            <div class="project-details">
                <h5>Foundational LMS Research</h5>
                <p>During our early years, the NLMSF supported numerous small-scale research projects that laid the groundwork for our current understanding of LMS biology and treatment. These initial investments helped establish LMS-specific research programs at several major institutions.</p>
                <p class="grant-note">Total Grants: $350,000</p>
            </div>
        </div>
    </section>

    <section class="impact-section">
        <h3>Research Impact</h3>
        <p>
            The research funded by NLMSF has contributed significantly to our understanding of Leiomyosarcoma and has led to several important advances in diagnosis and treatment. Many of the projects we've supported have resulted in peer-reviewed publications, clinical trials, and new therapeutic approaches.
        </p>
        <p>
            We remain committed to funding innovative research that has the potential to improve outcomes for LMS patients. If you're interested in supporting our research initiatives, please consider making a donation.
        </p>
        <a href="/donate" class="donate-button">Support LMS Research</a>
    </section>
</div>
